More on Athersys drug failure

Shares of cell therapy firm Athersys (ATHX -56.4%) nosedive after its MultiStem treatment for ulcerative colitis (UC) fails to show a meaningful benefit after eight weeks following a single administration in UC patients who have not responded to other therapies in a Phase 2 clinical trial.

The primary efficacy endpoints were a change in endoscopic score from baseline as measured by modified Baron score at eight weeks and the change in Mayo rectal bleeding subscore from baseline at four and eight weeks.

At four weeks, the proportion patients responding to the therapy was much greater than placebo but the benefit was offset by declines in a minority of MultiStem-treated patients.

16-week data, including the impact of second round dosing for a subset of patients, is still being evaluated.

Comments (8)
  • toosmarttofail
    , contributor
    Comments (706) | Send Message
    Non-embryonic stemcells are junk-science that became popular among politicians looking to avoid religious opposition, and scientists who told them what they wanted to hear in order to get funding. Only Dr. Robert Lanza of ACTC was undeterred, and ACTC owns the embryonic cell space, which just skyrocketed in value yet again.


    The patents are only part of the story. Lanza is also the most brilliant doctor, and will do the most with the science going forward. ACTC is about to make a clean sweep of this entire sector. I'm guessing CUR will be the next to fall, then NBS, then PSTI and OSIR, and then NWBO, MESO, and AGEN, while IMUC won't recover either.


    Phase II is where non-embryonic cell companies go to die.
    28 Apr 2014, 02:20 PM Reply Like
  • 11137741
    , contributor
    Comments (240) | Send Message
    Complete Failure even on multi dosed patients. No efficacy at all. That shows it is worthless everywhere when healing.


    I think the company is worthless now and don't know how it is holding 1.50 amazing... Stroke, maybe they can slow the spleen down a little. Big deal, it is working on anything else and I think we are seeing MAPCs are worthless compare to MSC's.


    Both, get a lot of Govt money, MY MONEY! Your money... And this company is front and center in your face about "we are Great" !We have a great product, look, we are manufacturing it, so it must work... Really a sad week in stem cell therapy future. After all these years, finally, we thought, it is to the point where it will work... NADA....


    Gonna look for a high and short it, adding on the next data, second half of this wasted phase II should bring it down. THen again on the CC when they report "0" earnigns....
    1 May 2014, 06:25 PM Reply Like
  • iberia
    , contributor
    Comments (44) | Send Message
    What about overweight treatment?
    9 May 2014, 11:10 AM Reply Like
  • wiseone123
    , contributor
    Comments (489) | Send Message
    Let's wait for the earnings release on May 8th. Perhaps some large Japanese Pharmaceutical Company will announce it is buying the entire company for $4.00 per share (dirt cheap) in order to cash in on a possible efficacy for stroke, a huge killer in Japan with 27% of its population over age 65 (the highest in the world). It is a small price for a huge gamble. Pfizer is bidding $100 billion for Astra-Zeneca, so a couple hundred million for ATHX is chump change.
    2 May 2014, 01:20 PM Reply Like
  • iberia
    , contributor
    Comments (44) | Send Message
    Sometimes bad news gets its positive side. And I'm not talking about the new opportunity to buy ATHX cheaper than before. Not only.
    For exemple, the discovery of the penicilin occured whereas Dr. Fleming tried to discover a remedy against flu. Actually a positive side-effect of its own.
    In this respect, I wouldn't be surprised if an efficient treatment against obesity should surge from the current developments of ATHX programs.
    It's nothing but my own intuition, but... who knows?
    9 May 2014, 10:09 AM Reply Like
  • iberia
    , contributor
    Comments (44) | Send Message
    What about the overweight treatment?
    9 May 2014, 11:04 AM Reply Like
  • wiseone123
    , contributor
    Comments (489) | Send Message
    Someone has to bail ATHX out if stroke shows no efficacy. My guess is it will be big Japanese Pharma if they find something in all of ATHX's research data worth purchasing. Japanese companies though usually not as innovative as those in the USA are much better at pursuing continuous improvement to products if there is something to improve upon. It is unlikely that ATHX can raise more money if stroke fails and the fact is that their cash position may be depleted after the next 18 months. Are their patents of any value? Can a merger be structured if there is something there of worth? No so sure why they think stroke may succeed when UC failed.
    10 May 2014, 01:11 PM Reply Like
  • 50245055
    , contributor
    Comment (1) | Send Message
    Where is Seeking Alpha now. Where are the glorified articles to support stem cell therapy now. I hope the authors had a bad financial loss similar to the devastation of my retirement account. I will hold the stock long term, but it really has the smell of pipe dreams gone awry...
    10 May 2014, 06:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs